Purine metabolism in two human melanoma cell lines: relation to proliferation and differentiation.
Purine nucleotide metabolism was studied in two human cutaneous melanoma cell lines IPC182 and IGR221. IPC182 cells do not differentiate, while IGR221 cells differentiate spontaneously at confluency, with intense melanin production. The activities of 11 enzymes involved in the de novo or salvage synthesis or the catabolic pathway of purine nucleotides were measured at different times (from day 3 to day 18), after subculture, during exponential growth and the stationary phase, with or without differentiation. The results demonstrated remarkable differences in the enzyme activity levels and/or the evolution from exponential growth to the stationary phase for each cell line, as well as between the two cell lines. In the non-differentiating IPC182 cells, the activity of enzymes involved in purine nucleotide synthesis decreased when the growth rate slowed down and remained at a low level with a concomitant increase in catabolic activities. In the differentiating IGR221 cells, the activity of enzymes involved in purine nucleotide salvage synthesis increased during the proliferative phase and was maintained at a high level when the cells reached confluency and differentiated; catabolic activities were always lower than in the IPC182 cells. This suggests that extra purine nucleotides, synthesized preferentially by the salvage pathway, could be required for the differentiation of human melanoma cells. Since the two cell lines were cultured in the absence of any differentiation-inducing agents, these results indicate that various metabolic modifications are associated with the natural processes of cell proliferation and differentiation. This research could help to identify some of the enzymes involved in purine metabolism as the targets for the induction of differentiation.
Wei
S
S
CEA, DSV/DRR/LRCE, Fontenay aux Roses, France.
Reillaudou
M
M
Apiou
F
F
Peyre
H
H
Pétridis
F
F
Luccioni
C
C
D015720:5'-Nucleotidase / Q000378:metabolism; D000228:Adenine Phosphoribosyltransferase / Q000378:metabolism; D000243:Adenosine Deaminase / Q000378:metabolism; D000248:Adenosine Kinase / Q000378:metabolism; D000263:Adenylate Kinase / Q000378:metabolism; D000264:Adenylosuccinate Lyase / Q000378:metabolism; D000619:Aminohydrolases / Q000378:metabolism; D002452:Cell Count; D002454:Cell Differentiation; D002455:Cell Division; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000378:metabolism; D007168:IMP Dehydrogenase / Q000378:metabolism; D008543:Melanins / Q000096:biosynthesis / Q000378:metabolism; D008545:Melanoma / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology*; D011683:Purine-Nucleoside Phosphorylase / Q000378:metabolism; D011687:Purines / Q000378:metabolism*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D008543:Melanins; D011687:Purines; D007168:IMP Dehydrogenase; D011683:Purine-Nucleoside Phosphorylase; D000228:Adenine Phosphoribosyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D000248:Adenosine Kinase; D000263:Adenylate Kinase; D015720:5'-Nucleotidase; D000619:Aminohydrolases; C018774:adenine deaminase; D000243:Adenosine Deaminase; D000264:Adenylosuccinate Lyase